This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Jun-Qiang Chen, Wen-Hua Zhan, Yu-Long He, Jun-Sheng Peng, Yi-Hua Huang, Zhen-Xuan Chen, Shi-Rong Cai, Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, Guangdong Province, China
Correspondence to: Dr. Wen-Hua Zhan, Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, Guangdong Province, China. wzwk@gzsums.edu.cn
Received: May 14, 2003 Revised: May 25, 2003 Accepted: June 4, 2003 Published online: January 15, 2004
AIM: To determine the most effective means of treating liver metastases from gastric cancer.
METHODS: We retrospectively examined 26 patients with liver metastases, but without peritoneal dissemination, who had received synchronous hepatic resection and curative gastrectomy, and noncurative gastrectomy.
RESULTS: The median survival times of patients given curative gastrectomy and noncurative gastrectomy were 398 and 202 d, respectively. The patients given curative gastrectomy survived significantly longer than those noncurative gastrectomy (P = 0.0 072). One patient survived for more than 8 years without any signs of recurrence. 1-year, 2-year and 3-year survival rates of patients who underwent curative gastrectomy were 51.2%, 44.9% and 18.2%, respectively. Those with noncurative gastrectomy were 14.6%, 0% and 0%, respectively.
CONCLUSION: Curative gastrectomy is best indicated for gastric cancer patients with solitary metastastic nodule or nodules limited in one lobe of the liver, which may improve the patients prognosis and extend their survival.
Key Words: N/A
Citation: Chen JQ, Zhan WH, He YL, Peng JS, Huang YH, Chen ZX, Cai SR. Surgical treatment for synchronous hepatic metastases from gastric cancer: A report of 12 cases. Shijie Huaren Xiaohua Zazhi 2004; 12(1): 6-8
Maehara Y, Kakeji Y, Oda S, Takahashi I, Akazawa K, Sugimachi K. Time trends of surgical treatment and the prognosis for Japanese patients with gastric cancer.Br J Cancer. 2000;83:986-991.
[PubMed] [DOI]
Fujisaki S, Tomita R, Nezu T, Kimizuka K, Park E, Fukuzawa M. Prognostic studies on gastric cancer with concomitant liver metastases.Hepatogastroenterology. 2001;48:892-894.
[PubMed] [DOI]
Moriya A, Hyodo I, Nishina T, Imaoka H, Imagawa A, Doi T, Endo H, Tanimizu M, Tajiri H. Extensive liver metastasis of gastric cancer effectively treated by hepatic arterial infusion of 5-fluorouracil/cisplatin.Gastric Cancer. 2000;3:110-115.
[PubMed] [DOI]
Sakamoto Y, Ohyama S, Yamamoto J, Yamada K, Seki M, Ohta K, Kokudo N, Yamaguchi T, Muto T, Makuuchi M. Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients.Surgery. 2003;133:507-511.
[PubMed] [DOI]
Yagi Y, Seshimo A, Kameoka S. Prognostic factors in stage IV gastric cancer: univariate and multivariate analyses.Gastric Cancer. 2000;3:71-80.
[PubMed] [DOI]
Maehara Y, Tomisaki S, Oda S, Sakaguchi Y, Ichiyoshi Y, Sugimachi K. Lymphatic advancement to peritoneal dissemination and liver metastasis in gastric cancer patients.Anticancer Res. 1994;14:2755-2758.
[PubMed] [DOI]
Kumada T, Arai Y, Itoh K, Takayasu Y, Nakamura K, Ariyoshi Y, Tajima K. Phase II study of combined administration of 5-fluorouracil, epirubicin and mitomycin-C by hepatic artery infusion in patients with liver metastases of gastric cancer.Oncology. 1999;57:216-223.
[PubMed] [DOI]
Iwahashi M, Tanimura H, Nakamori M, Nagai Y, Hirabayashi N, Ueda K, Matsuda K, Tsunoda T, Yamaue H. Clinical evaluation of hepatic arterial infusion of low dose-CDDP and 5-FU with hyperthermotherapy: a preliminary study for liver metastases from esophageal and gastric cancer.Hepatogastroenterology. 1999;46:2504-2510.
[PubMed] [DOI]
Hanazaki K, Sodeyama H, Mochizuki Y, Igarashi J, Yokoyama S, Sode Y, Wakabayashi M, Kawamura N, Miyazaki T. Palliative gastrectomy for advanced gastric cancer.Hepatogastroenterology. 2001;48:285-289.
[PubMed] [DOI]
Kumagai K, Tanaka T, Yamagata K, Yokoyama N, Shimizu K. Liver metastasis in gastric cancer with particular reference to lymphatic advancement.Gastric Cancer. 2001;4:150-155.
[PubMed] [DOI]
Benevento A, Boni L, Frediani L, Ferrari A, Dionigi R. Result of liver resection as treatment for metastases from noncolorectal cancer.J Surg Oncol. 2000;74:24-29.
[PubMed] [DOI]
Takata N, Harada K, Yoshinaka I, Maeda M, Nasu J, Ikeda R. Multimodality therapy for synchronous liver metastases of gastric cancer-significance of aggressive hepatic resection of liver lesions.Gan To Kagaku Ryoho. 2000;27:1916-1919.
[PubMed] [DOI]
Okuno K, Shigeoka H, Tanaka A, Hirai N, Matsumura E, Yasutomi M. Clinicopathological evaluation of T2-gastric cancer among age groups.Hepatogastroenterology. 2000;47:1180-1182.
[PubMed] [DOI]
Tsujitani S, Oka S, Suzuki K, Saito H, Kondo A, Ikeguchi M, Maeta M, Kaibara N. Prognostic factors in patients with advanced gastric cancer treated by noncurative resection: a multivariate analysis.Hepatogastroenterology. 2001;48:1504-1508.
[PubMed] [DOI]
Morise Z, Yamafuji K, Takahashi T, Asami A, Takeshima K, Hayashi N, Fukazawa A, Yoshida F, Yamamoto M, Tokura Y. Successful treatment of recurrent liver metastases from gastric cancer by repeated hepatic resections: report of a case.Surg Today. 2000;30:1041-1045.
[PubMed] [DOI]
Kunieda K, Saji S, Sugiyama Y, Osada S, Sano J, Nagao N, Takahashi T, Takagi Y, Arai Y. Evaluation of treatment for synchronous hepatic metastases from gastric cancer with special reference to long-term survivors.Surg Today. 2002;32:587-593.
[PubMed] [DOI]
Ambiru S, Miyazaki M, Ito H, Nakagawa K, Shimizu H, Yoshidome H, Shimizu Y, Nakajima N. Benefits and limits of hepatic resection for gastric metastases.Am J Surg. 2001;181:279-283.
[PubMed] [DOI]
Saiura A, Umekita N, Inoue S, Maeshiro T, Miyamoto S, Matsui Y, Asakage M, Kitamura M. Clinicopathological features and outcome of hepatic resection for liver metastasis from gastric cancer.Hepatogastroenterology. 2002;49:1062-1065.
[PubMed] [DOI]
Nashimoto A, Yabusaki H, Takii Y, Tsuchiya Y, Tanaka O. Evaluation of hepatic resection for metachronous liver metastases from gastric cancer.Gan To Kagaku Ryoho. 2002;29:2096-2099.
[PubMed] [DOI]
Yoshizumi Y, Matuyama T, Koike H, Aiko S, Sugiura Y, Maehara T. Long-term survival after gastric cancer and liver and paraaortic lymph node metastases: report of a case.Surg Today. 2001;31:159-162.
[PubMed] [DOI]
Aoyagi K, Koufuji K, Yano S, Murakami N, Miyagi M, Takeda J, Shirouzu K. Long-term survival after gastric cancer with liver metastasis: a report of two cases.Kurume Med J. 2001;48:335-338.
[PubMed] [DOI]
Yano S, Koufuji K, Aoyagi K, Murakami N, Terasaki Y, Miyagi M, Takeda J, Shirouzu K. A patient with advanced gastric cancer, underwent curative gastrectomy and partial resection of metachronous hepatic metastases, is surviving for 13 years to date.Kurume Med J. 2002;49:53-56.
[PubMed] [DOI]